{"id":531639,"date":"2021-02-24T18:38:01","date_gmt":"2021-02-24T18:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531639"},"modified":"2021-02-24T18:38:01","modified_gmt":"2021-02-24T18:38:01","slug":"psoriasis-epidemiology-forecast-to-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/psoriasis-epidemiology-forecast-to-2030-by-delveinsight_531639.html","title":{"rendered":"Psoriasis Epidemiology Forecast to 2030 by DelveInsight"},"content":{"rendered":"
\"Psoriasis<\/a><\/div>\n

DelveInsight has launched a new report on Psoriasis Epidemiology<\/a><\/strong><\/p>\n

 <\/p>\n

Psoriasis is a chronic, immune mediated inflammatory skin disease characterized by the presence of papules and plaques occurring most commonly on the elbows, knees, scalp, and lower back, but is not limited to these areas. Psoriasis has a both pediatric and adult onset with the former accounting for more number of cases. Plaques vary in terms of variable morphology, distribution and severity. Psoriatic patients are frequently categorized into two groups: mild or moderate to severe psoriasis, depending on the clinical severity of the lesions, the percentage of affected body surface area, and patient quality of life.<\/p>\n

 <\/p>\n

Request for free sample copy<\/strong>– https:\/\/www.delveinsight.com\/sample-request\/psoriasis-epidemiology-forecast<\/a><\/strong><\/p>\n

 <\/p>\n

The Psoriasis Epidemiology<\/strong> Report covers the overview, treatment practice and forecasted epidemiology of Psoriasis Epidemiology<\/strong> from 2020 to 2030<\/p>\n

 <\/p>\n

Psoriasis Epidemiology <\/strong><\/p>\n

As per WHO (World Health Organization), Psoriasis is a chronic, noncommunicable, painful, disfiguring and disabling disease for which there is no cure and with great negative impact on patients’ quality of life (QoL). It can occur at any age, and is most common in the age group 50–69. The reported prevalence of psoriasis in countries ranges between 0.09% and 11.4%, making psoriasis a serious global problem. The study quoted data on the prevalence in the United States from the National Health and Nutrition Examination Survey, indicating an increase in prevalence from 1.62% to 3.10% from 2004 to 2010.<\/p>\n

 <\/p>\n

Key facts of<\/strong> Psoriasis Epidemiology <\/strong><\/p>\n